

Pediatric Chronic Hand Eczema: Epidemiology, Clinical Presentation and Management Issues

Michael A. Haft, MD, Helen H. Park, MD, Stephanie S. Lee, MD, Jessica M. Sprague, MD, Lawrence F. Eichenfield, MD

PII: S2666-3287(23)00035-4

DOI: https://doi.org/10.1016/j.jdin.2023.02.008

Reference: JDIN 341

To appear in: *JAAD International*

Received Date: 14 December 2022

Revised Date: 13 February 2023

Accepted Date: 19 February 2023

Please cite this article as: Haft MA, Park HH, Lee SS, Sprague JM, Eichenfield LF, Pediatric Chronic Hand Eczema: Epidemiology, Clinical Presentation and Management Issues, *JAAD International* (2023), doi: https://doi.org/10.1016/j.jdin.2023.02.008.

Article type: Review

Title: Pediatric Chronic Hand Eczema: Epidemiology, Clinical Presentation and Management Issues

Running heading: Pediatric Chronic Hand Eczema

Michael A. Haft, MD[1,2], Helen H. Park, MD[1,2], Stephanie S. Lee, MD[1,2], Jessica M. Sprague, MD[1,2], Lawrence F. Eichenfield, MD[1,2]

[1]Rady Children's Hospital, San Diego, Division of Pediatric and Adolescent Dermatology, 3020 Children's Way, San Diego, CA 92130

[2]University of California, San Diego, School of Medicine, Department of Dermatology, 9500 Gilman Drive, MC 0869, La Jolla, CA 92093-0869

Manuscript word count (Max is 2500 words): 2585 words [excluding abstract, abbreviations list, references, figures, tables]

Abstract word count (Max is 200 words): 158 words

Capsule Summary Word Count: 49 words

References: 62

Figures: 0

Supplementary figures: 0

Tables: 4

Supplementary tables: 0

Attachments: Cover Letter

Funding: Internal funding from the University of California, San Diego's Department of Pediatric Dermatology is funding the publication of this investigation.

Statements and Declarations:

Declaration of interest:

Lawrence F. Eichenfield, MD has served as an advisory board member, and/or speaker, consultant, or clinical trial investigator for AbbVie, Arcutis, Almirall, Arena, Aslan, Bausch, Castle, Dermavant, Eli Lilly, Forte, Galderma, Gelnmark/Ichnos, Incyte, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Valeant/Ortho

Derm. Michael A. Haft, MD, Helen H. Park, MD, Stephanie S. Lee, MD, and Jessica M. Sprague, MD declare that they have no conflict of interest.

Availability of data and material: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Code availability: Not applicable

Authors' contributions: Conceptualization: Michael A. Haft, Lawrence F. Eichenfield; Methodology: Michael A. Haft, Helen H. Park, Stephanie S. Lee, Jessica M. Sprague, Lawrence F. Eichenfield; Formal analysis and investigation: Michael A. Haft, Helen H. Park, Stephanie S. Lee, Jessica M. Sprague, Lawrence F. Eichenfield; Writing - original draft preparation: Michael A. Haft; Writing - review and editing: Michael A. Haft, Helen H. Park, Stephanie S. Lee, Jessica M. Sprague, Lawrence F. Eichenfield; Resources: Lawrence F. Eichenfield; Supervision: Jessica M. Sprague, Lawrence F. Eichenfield.

Ethics Approval: Not applicable as the investigation utilized publicly available and published data to generate a review.

Consent to participate: Not applicable

Consent for publication: Not applicable

Reprint requests: Lawrence F. Eichenfield

Statement on prior presentation: Neither the article nor its contents have been presented at a prior presentation by the authors of this article.

Corresponding author:
Lawrence F. Eichenfield, MD
3020 Children's Way
Mail Code 5092
San Diego, CA 92130
Telephone number: 858-966-1700 ext.224295
Email: leichenfield@rchsd.org, tvbeck@rchsd.org

Abstract:

Chronic hand eczema is a persistent inflammatory dermatitis that may significantly affect quality of life, with psychosocial effects, impact on school, work, and leisure activities, influence on socioeconomic status, and high healthcare costs. Pediatric chronic hand eczema has a high prevalence yet has not been extensively studied in children and adolescents. There is minimal published data on pediatric chronic hand eczema in North America, and no specific management guidelines. Limited prevalence data shows broad ranges (0.9-4.4%) in pre-school and school children, with one study stating up to 10.0% one-year prevalence for ages 16-19 years. Atopic dermatitis and allergic contact dermatitis appear important in the pathogenesis of this disease process, though there is limited pediatric data assessing disease associations and no standardized methodology for evaluating this disorder. Given the potential life-changing consequences of pediatric chronic hand eczema, further research into this disease process is warranted to help generate best therapeutic practices and minimize this disease process' morbidity into adulthood.

Capsule summary (Max word count of 50 words):

- Pediatric chronic hand eczema has a high prevalence yet has not been extensively studied in children and adolescents with no guidelines on its management
- This review on pediatric chronic hand eczema highlights major findings in the literature and supports the need for further investigation into this life-changing disease process

Keywords: Pediatric, Child, Children, Childhood, Adolescent, Teenage, Teenager, Young, Chronic, Persistent, Recalcitrant, Hand, Manus, Eczema, Dermatitis, Skin, Review, Literature, Summary, Questions

Introduction:

Chronic hand eczema (CHE) is defined by Deipgen et al. as hand eczema with symptoms persisting for greater than 3 months or with symptoms returning twice or more within 12 months.[1] CHE significantly affects quality of life, has financial and psychosocial consequences which include job loss and high healthcare burdens, and can harm self-esteem and interpersonal relationships.[2-4] The published literature on CHE in children and adolescents is limited. We evaluate and summarize pediatric chronic hand eczema (P-CHE) epidemiology, risk factors, disease associations, clinical presentations, severity classifications, diagnostic assessment, and therapeutic interventions. Knowledge gaps that might drive future research are identified.

Materials and methods:

Systematic search of PubMed, Embase and Cochrane databases was performed from inception through December 5, 2022, for studies utilizing search terms *hand eczema, hand dermatitis, hand* and *eczema* or *dermatitis* in children, restricted to English-language articles. Records were screened according to title and abstracts (985 records), duplicates removed (112), and article eligibility determined by including primary literature or review articles, observational or controlled studies, scope including patients aged 0-20 years, and a diagnosis of hand dermatitis or eczema, yielding 31 manuscripts.

Prevalence in Children and Adolescents:

Multiple investigations found that P-CHE is common, with lifetime prevalence of 6.5-13.3% and a 1-year prevalence of 5.2-10.0% (Table I).[5-10] Figures of prevalence in children vary, with lower prevalence at younger ages. Wang et al. found that the median age of first occurrence of hand eczema in children was 12 years.[10] Grönhagen et al. reported hand eczema incidence rates of approximately 0.9% per year in children ages 0-5 and 6-11 years old and approximately 1.6% in children ages 12-16 years old.[6] Yngveson et al. reported the point prevalence of hand eczema to be 3.9% (95% CI: 2.9-5.0%) in grade 1 students and 4.4% (95% CI: 3.3-5.5%) in grade 3 students in Sweden, though differences in data sets were not statistically significant.[9] Much lower childhood lifetime prevalence data was reported by Crane et al (0.012%), but the Depigen CHE diagnostic criteria were not utilized.[11] Overall prevalence data correlates with general population data in both children and adults that demonstrates a lifetime prevalence of about 15% globally.[12]

Most studies report that female children are more affected than males, carrying a life-time prevalence of 11.2-16.2% (vs. 6.3-9.6%) and a 1-year prevalence of 6.4-12.5% (vs 4.0-7.3%) (Table I).[6-10] Two studies have reported higher rates of adult women developing hand eczema before age 20 years (35% and 50%) than men (27% and 42%),[13,14] and Röhrl and Stenberg observed a positive relationship between hand eczema and female sex (Table II).[15] However, two recent robust investigations did not find statistically significant odds of P-CHE by sex (Table II).[10,16] Conflicting sex-difference data in children contrasts with sex-stratified broader population data demonstrating greater prevalence in the female population.[12]

Although these analyses utilize large subject populations, these investigations carry a number of issues, including recall bias, overestimating the number of participants with hand eczema, and limiting most data sets to one city in one European nation.[5-10,13-15] Thus, they may not reflect P-CHE's global epidemiology.

Symptoms, Distribution, and Morphology:

Symptoms and signs of CHE include itch, redness, scaling, oozing, crusting, and burning pain.[17-19] While symptoms may be important in assessing P-CHE severity and as potentially measurable parameters in clinical studies, there is minimal data on signs and symptoms in children and adolescents. Mortz et al. found that children with hand eczema commonly report pruritus (82.7%), erythema (62.4%), and dry skin with scaling (54.1%).[8] Simonsen et al. found 26.2% of parents of children with hand eczema reported moderate to severe burning of the hands, 23.2% with moderate to severe pruritis, 12.6% with moderate to severe pain, and 6.5% with sleep disturbance.[20] Five investigations reviewed the distribution of lesions in children with hand eczema and found areas of involvement to be variable. Depending on the study, the most commonly reported locations were dorsal hands,[5] finger webs or fingers,[8,21] palms,[22] fingertips, or diffuse hand involvement (Table III).[23] Small data sets and reliance on self-reporting may explain inconsistencies between studies.

Few investigations assessed P-CHE severity. One study of 133 children who reported symptoms of hand eczema in the last 12 months found that 44% lacked any signs or symptoms at the time of evaluation, whereas 13% had moderate disease and 14% severe disease utilizing the Hand Eczema Extent Score (HEES). Researchers did not specify how many investigators examined the hands of participants, resulting in possible measurement bias.[6] Another study of 9 children with P-CHE found an average Hand Eczema Severity Index (HECSI) score correlating

to severe disease prior to initiation of alitretinoin therapy, but there was selection bias as all children failed multiple therapies before starting alitretinoin.[24,25]

These 6 studies constitute the bulk of the literature on the signs, symptoms, disease course and outcomes of in pediatrics. Hand eczema studies in adults show that the disease process presents with edema, erythema, or vesiculation in its acute form, and fissuring, scaling, or crusting chronically.[19] In a twin cohort study based in Denmark, of those with hand eczema, 52.3% reported scaling, 51.4% reported erythema, 29.7% reported fissuring, and 20.7% reported vesicles. Of the 77 adults clinically examined, 47.7% had findings on the fingers (excluding fingertips), 35.1% on the palms of hands, 30.6% on fingertips, and 24.3% on dorsal hands.[26] Comparisons of these adult and pediatric data sets are insufficient given the small data sets and reliance on self-reporting in some investigations.

Unanswered questions remain regarding P-CHE's presentation. Like the data available on prevalence, the published data is limited to Northern Europe. Course and symptom complex are not well categorized in the pediatric population. Further research into signs and symptoms of this disease presentation in children and adolescents would be useful.

Risk Factors and Diagnoses:

Multiple studies suggest that CHE is strongly associated with atopic dermatitis (AD) in children. In one study, 43.7% of 0-2 year olds and 54.1% of 3-12 year olds with AD had hand eczema, though chronicity or duration were not noted.[27] Two investigations from Mortz et al. and one from Grönhagen et al. found odds ratios of 3.7-5.61 between childhood hand eczema and AD (Table II).[8,28,29] In an evaluation of pediatric patients referred for patch testing to the North American Contact Dermatitis Group, children with hand eczema were more likely to have a diagnosis of AD than adults.[16] Mortz et al. in 2015 found an odds ratio of 4.3 between hand eczema in childhood and persistent AD in adulthood,[30] while Wang et al. in 2021 calculated an adjusted odds ratio of 1.8 between previous diagnosis of AD and lifetime incidence of hand eczema in 15 year olds.[10] Data regarding AD age of onset and hand eczema risk is conflicting. Wang et al. reported a statistically significant adjusted odds ratio of 1.8 between early age of onset of AD, independent of the diagnosis of AD itself, and pediatric hand eczema.[10] However, Grönhagen et al. found no differences between odds ratios of hand eczema and AD at different onset ages of AD.[28] With regards to hand eczema's relationship to generalized eczema, Silverberg et al. found that hand eczema was

associated with lower proportions of generalized dermatitis.[16] Although filaggrin mutations are believed to be among the strongest risk factors for developing AD,[31] a logistic regression analysis performed by Lagrelius et al. found no statistically significant odds ratio between filaggrin gene mutations and P-CHE.[32]

The data on the relationship of inhalant allergy to pediatric hand eczema is inconsistent. Röhrl and Stenberg found significant associations between hand eczema and asthma as well as hand eczema and allergic rhinoconjunctivitis (Table II), but memory bias and use of invalidated questions in this investigation may have skewed results.[15] Four other investigations found no such links (Table II).[8,10,16,28] Given this discrepant data, these relationships must be further investigated.

P-CHE may also be associated with allergic contact dermatitis (ACD).[29,33] One investigation of children with AD found that 43.8% of children with hand and/or foot eczema had contact allergy versus 16.0% of children without hand or foot dermatitis.[33] Another study found that 35.7% of patients with ACD had hand involvement.[34] Patch testing of children with hand eczema reveals that the most common or most relevant allergens associated with the disorder include nickel, methylchloroisothiazolinone (MCI) / methylisothiazolinone (MI) (which are commonly found in cosmetic, hygiene, and household products), and cobalt.[16,22,35-40] Nickel and MI sensitization stand out as major risk factors for P-CHE, with other allergens less common. Adult population data carries similar findings, as one report found the most frequent sensitizers in adults with hand eczema to be nickel, MCI/MI, cobalt chloride, and fragrance mix I.[41]

The evidence of irritant contact dermatitis' (ICD) influence on P-CHE is less clear. In 2020 and 2021, Simonsen et al. found that 26.2% of 0-7 year olds and 36.3% of 5-13 year olds investigated developed hand eczema following strict hand hygiene protocols upon return to daycare or school in the middle of the COVID-19 pandemic, with frequency of handwashing, female gender, and history of atopic dermatitis associated with increased risk of developing hand eczema.[20,42] However, in a 2017 study by Meding et al., investigators found no association between pediatric hand eczema and hand-water exposure.[43]

P-CHE has several coupled diagnoses. Two studies found the most common final diagnoses of children with P-CHE to be ACD, AD, and vesicular (dyshidrotic) eczema (Table IV).[22,23] Another found the most common diagnoses for children with CHE referred for patch testing to be ACD, AD, and ICD (Table IV).[16] This suggests that ACD and AD are commonly associated with CHE in childhood. The adult CHE literature presents some overlap in findings, with one analysis presenting the most common associated diagnoses as combinations of ICD, ACD, and

vesicular eczema,[1] suggesting that AD plays a greater role in P-CHE pathogenesis with ICD playing a greater role in adult CHE. In clinical practice, it appears that some children and adolescents have significant chronic hand dermatitis as part of a constellation of findings in active AD, while others have localized CHE, or predominate issues with CHE disproportionate to other issues with AD. We believe the term CHE remains useful, with subcategories of etiology including AD and ACD.

Investigations show conflicting data regarding the influence of inhalant allergy and ICD on P-CHE. AD and ACD's overlap with and impact on P-CHE are much clearer,[16] and evidence demonstrates nickel and MI allergy's influence on hand eczema in children. Further investigations need to elucidate the relationship of these and other risk factors for the development and persistence of CHE in childhood.

Many methods of diagnosis/classification of CHE[44-47] attempt to incorporate various combinations of morphology, etiology, and chronological progression, while major studies have found insignificant association between classification and etiology.[45,46,48]

Diagnostic Testing, Severity Assessment, and Therapeutics:

P-CHE workup frequently includes patch testing with studies finding that anywhere from 14.5-28.0% of children referred for patch testing have hand eczema.[16,22,35,49] In two studies, patch testing was reported to have a clinical relevance of 78% in P-CHE and 76.2% in pediatric hand eczema,[22,50] much higher than in adult studies.[51,52] The literature has not supported IgE testing as no association has been found between positive specific IgE during childhood and P-CHE.[28]

The use of standardized severity assessments are rare in the P-CHE literature, with one P-CHE study utilizing the HECSI and Investigator Global Assessment (IGA)[24] and one study utilizing the HEES.[6] Other evaluation measures, including the Dermatology Life Quality Index (DLQI),[17] Quality of Life in Hand Eczema Questionnaire (QOLHEQ),[53] and modified total lesion symptom score (mTLSS)[54] appear to only be executed in adult populations or in studies containing mixed populations of both children and adults.[55]

Studies evaluating topical or systemic medications for P-CHE are limited. In a retrospective analysis of 13 children who received systemic alitretinoin therapy, 9 were children with CHE. In this subgroup, 7/9 had moderate to excellent results on alitretinoin.[24] In retrospective review of 75 children receiving phototherapy for cutaneous

conditions, 4 had severe hand eczema, of which 3 had clinical improvement after psoralen and ultraviolet A (PUVA) therapy.[56] In a 2019 systematic review of publications on hand eczema therapeutics performed by Christoffers et al., researchers could not find a single study on therapeutics exclusively in pediatrics. Most of the studies excluded children and pediatric patients were not given their own subgroup analysis apart from adults in any article.[57]

Although the literature lacks published data on P-CHE treatment, investigators from this article and the Pediatric Dermatology Research Alliance, performed a survey of pediatric dermatologist CHE experts. Surveyed respondents all utilize topical corticosteroids (TCS) as first line topical therapy with most choosing TCS, topical calcineurin inhibitors, and topical phosphodiesterase-4 inhibitors as second line agents. Systemic treatment use is rare, with most respondents reporting 5 or fewer patients treated for the indication of P-CHE. The most preferred systemic agent for P-CHE was dupilumab, followed by methotrexate.[58]

No specific guidelines exist for P-CHE management, though there are published guidelines and consensus statements for the management of CHE based on adult data.[59,60] The European Society of Contact Dermatitis (ESCD) produced updated management guidelines for hand eczema in 2022, recommending the use of patch testing in all patients with CHE. Other recommendations included skin prick testing, microbial testing, and cutaneous biopsy when deemed appropriate. However, there is significant disagreement among experts concerning utility of patch testing irrespective of morphology and location, predictive value of testing, and cost effectiveness.[48] Management includes prevention and use of therapeutics from emollients and topical steroids to systemic agents such as oral alitretinoin (approved for CHE in Europe and the United Kingdom) or cyclosporin.[61] Recent literature highlights the use of emerging and investigational systemic agents including biologic agents and JAK inhibitors for CHE in adults.[62]

The lack of scoring systems, published data on therapeutics, and management guidelines focused on the pediatric population is troubling given the life-altering potential of this disorder.[4] Utilization of standardized metrics of disease severity, quality of life, and treatment response could assist in determining the comparative efficacy of various interventions and guide the development of best practices guidelines.

Future Directions and Significance of Further Investigations:

There remain wide knowledge gaps in the epidemiology, presentation, risk stratification, diagnosis, and management of CHE in pediatric populations. Most published studies are limited to patients in Northern Europe.

Most of the data on CHE epidemiology is based on adult patients.[12] While many adults report hand eczema onset in childhood, few reports investigate characteristics of this disease in the pediatric population, including assessing what percentage of children with hand eczema have AD. Even fewer studies have explored scoring systems in assessment or therapeutic management of P-CHE.

Numerous questions remain in all domains of this disorder in children and adolescents: What is the course of hand eczema in childhood versus adults? How does hand eczema in pediatrics progress from acute to chronic disease? What percentage of those affected have active AD or other inflammatory skin conditions? What are other risk factors for disease development? What classification systems are ideal? Why is there little consensus on features and testing? When would providers utilize certain tests for disease workup and treatments for disease management? How do clinicians assess treatment response? How does therapeutic data correlate with severity or quality of life scoring?

Early recognition and treatment of this disease process in childhood may minimize the disease impact, decrease healthcare burden, and improve quality of life.[4] Further investigations into the epidemiology of P-CHE onset and course, disease associations, comorbidities, and therapeutics are important to determine best practices to allow for comprehensive and successful management. With ongoing development of new topical and systemic agents for CHE as well as for AD, focused research on P-CHE is warranted.

Abbreviations and Acronyms:

ACD: Allergic Contact Dermatitis

AD: Atopic Dermatitis

CHE: Chronic Hand Eczema

CI: Confidence Interval

DLQI: Dermatology Life Quality Index

ESCD: European Society of Contact Dermatitis

HE: Hand Eczema

HECSI: Hand Eczema Severity Index

HEES: Hand Eczema Extent Score

ICD: Irritant Contact Dermatitis

IGA: Investigator Global Assessment

MCI: Methylchloroisothiazolinone

MI: Methylisothiazolinone

NR: Not Reported

mTLSS: Modified Total Lesion Symptom Score

P-CHE: Pediatric Chronic Hand Eczema

PPD: Paraphenylenediamine

PUVA: Psoralen and Ultraviolet A

QOLHEQ: Quality of Life in Hand Eczema Questionnaire

Acknowledgements: None

References

1. Diepgen TL, Elsner P, Schliemann S, et al. Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30. *J Dtsch Dermatol Ges*. May 2009;7 Suppl 3:S1-16. doi:10.1111/j.1610-0387.2009.07061.x
2. Armstrong A, Hahn-Pedersen J, Bartlett C, Glanville J, Thyssen JP. Economic Burden of Chronic Hand Eczema: A Review. *Am J Clin Dermatol*. Mar 8 2022;doi:10.1007/s40257-021-00669-6
3. Ahmed A, Shah R, Papadopoulos L, Bewley A. An ethnographic study into the psychological impact and adaptive mechanisms of living with hand eczema. *Clin Exp Dermatol*. Jul 2015;40(5):495-501. doi:10.1111/ced.12619
4. Cazzaniga S, Ballmer-Weber BK, Grani N, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. *J Eur Acad Dermatol Venereol*. Apr 2016;30(4):628-37. doi:10.1111/jdv.13479
5. Dotterud LK, Falk ES. Contact allergy in relation to hand eczema and atopic diseases in north Norwegian schoolchildren. *Acta Paediatr*. Apr 1995;84(4):402-6. doi:10.1111/j.1651-2227.1995.tb13659.x
6. Gronhagen CM, Liden C, Bergstrom A, Kull I, Wahlgren CF, Meding B. Prevalence and incidence of hand eczema in adolescence: report from BAMSE--a population-based birth cohort. *Br J Dermatol*. Sep 2014;171(3):609-14. doi:10.1111/bjd.13194
7. Johannisson A, Ponten A, Svensson A. Prevalence, incidence and predictive factors for hand eczema in young adults - a follow-up study. *BMC Dermatol*. Oct 29 2013;13:14. doi:10.1186/1471-5945-13-14
8. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. *Br J Dermatol*. Mar 2001;144(3):523-32. doi:10.1046/j.1365-2133.2001.04078.x
9. Yngveson M, Svensson A, Isacsson A. Prevalence of self-reported hand dermatosis in upper secondary school pupils. *Acta Derm Venereol*. Sep 1998;78(5):371-4. doi:10.1080/000155598443097
10. Wang J, Tischer C, Standl M, et al. Lifetime prevalence and determinants of hand eczema in an adolescent population in Germany: 15-year follow-up of the LISA cohort study. *J Eur Acad Dermatol Venereol*. Nov 15 2021;doi:10.1111/jdv.17814
11. Crane MM, Webb DJ, Watson E, Cunliffe T, English J. Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment. *Br J Dermatol*. Apr 2017;176(4):955-964. doi:10.1111/bjd.14974
12. Thyssen JP, Johansen JD, Linneberg A, Menné T. The epidemiology of hand eczema in the general population--prevalence and main findings. *Contact Dermatitis*. Feb 2010;62(2):75-87. doi:10.1111/j.1600-0536.2009.01669.x
13. Meding B, Järvholm B. Incidence of hand eczema-a population-based retrospective study. *J Invest Dermatol*. Apr 2004;122(4):873-7. doi:10.1111/j.0022-202X.2004.22406.x
14. Vindenes HK, Svanes C, Lygre SHL, Hollund BE, Langhammer A, Bertelsen RJ. Prevalence of, and work-related risk factors for, hand eczema in a Norwegian general population (The HUNT Study). Article. *Contact Dermatitis*. 2017;77(4):214-223. doi:10.1111/cod.12800
15. Röhrl K, Stenberg B. Lifestyle factors and hand eczema in a Swedish adolescent population. *Contact Dermatitis*. Mar 2010;62(3):170-6. doi:10.1111/j.1600-0536.2009.01679.x

16. Silverberg JI, Warshaw EM, Maibach HI, et al. Hand Eczema in Children Referred for Patch Testing: North American Contact Dermatitis Group Data, 2000-2016. *Br J Dermatol*. Jan 16 2021;doi:10.1111/bjd.19818
17. Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults. *Patient*. Oct 2019;12(5):445-459. doi:10.1007/s40271-019-00373-y
18. Rademaker M, Armour K, Baker C, et al. Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative. *Australas J Dermatol*. Feb 2021;62(1):17-26. doi:10.1111/ajd.13418
19. Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. *J Eur Acad Dermatol Venereol*. Jan 2020;34 Suppl 1:4-12. doi:10.1111/jdv.16061
20. Simonsen AB, Ruge IF, Quaade AS, Johansen JD, Thyssen JP, Zachariae C. Increased occurrence of hand eczema in young children following the Danish hand hygiene recommendations during the COVID-19 pandemic. Article. *Contact Dermatitis*. 2021;84(3):144-152. doi:10.1111/cod.13727
21. Lee HJ, Ha SJ, Ahn WK, et al. Clinical evaluation of atopic hand-foot dermatitis. *Pediatr Dermatol*. Mar-Apr 2001;18(2):102-6. doi:10.1046/j.1525-1470.2001.018002102.x
22. Toledo F, García-Bravo B, Fernández-Redondo V, et al. Patch testing in children with hand eczema. A 5-year multicentre study in Spain. *Contact Dermatitis*. Oct 2011;65(4):213-9. doi:10.1111/j.1600-0536.2011.01943.x
23. Ortiz-Salvador JM, Subiabre-Ferrer D, Garcia Rabasco A, Esteve-Martinez A, Zaragoza-Ninet V, Alegre de Miquel V. [Hand eczema in children. Clinical and epidemiological study of the population referred to a tertiary hospital]. *An Pediatr (Barc)*. Jun 2018;88(6):309-314. Eccema de manos en ninos. Estudio clinico-epidemiologico de la poblacion remitida a un hospital terciario. doi:10.1016/j.anpedi.2017.07.005
24. Luchsinger I, Vogler T, Schwieger-Briel A, et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis. *J Eur Acad Dermatol Venereol*. May 2020;34(5):1037-1042. doi:10.1111/jdv.16088
25. Oosterhaven JAF, Schuttelaar MLA. Responsiveness and interpretability of the Hand Eczema Severity Index. *Br J Dermatol*. Apr 2020;182(4):932-939. doi:10.1111/bjd.18295
26. Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Clinical characteristics and consequences of hand eczema - an 8-year follow-up study of a population-based twin cohort. *Contact Dermatitis*. Apr 2008;58(4):210-6. doi:10.1111/j.1600-0536.2007.01305.x
27. Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. *Dermatitis*. Sep 2006;17(3):123-7. doi:10.2310/6620.2006.06005
28. Grönhagen C, Lidén C, Wahlgren CF, et al. Hand eczema and atopic dermatitis in adolescents: a prospective cohort study from the BAMSE project. *Br J Dermatol*. Nov 2015;173(5):1175-82. doi:10.1111/bjd.14019
29. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Contact allergy and allergic contact dermatitis in adolescents: prevalence measures and associations. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). *Acta Derm Venereol*. 2002;82(5):352-8. doi:10.1080/000155502320624087
30. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. *Allergy*. Jul 2015;70(7):836-45. doi:10.1111/all.12619

31. O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. *J Allergy Clin Immunol*. Oct 2008;122(4):689-693. doi:10.1016/j.jaci.2008.08.002
32. Lagrelius M, Wahlgren CF, Bradley M, et al. Filaggrin gene mutations in relation to contact allergy and hand eczema in adolescence. *Contact Dermatitis*. Mar 2020;82(3):147-152. doi:10.1111/cod.13444
33. Isaksson M, Olhardt S, Radehed J, Svensson A. Children with Atopic Dermatitis Should Always be Patch-tested if They Have Hand or Foot Dermatitis. *Acta Derm Venereol*. May 2015;95(5):583-6. doi:10.2340/00015555-1995
34. Yilmaz Z, Ozkaya E. Patch-test results in terms of the recently recommended allergens in children and adolescents: A retrospective cohort study over 22 years from Turkey. *Contact Dermatitis*. Mar 23 2021;doi:10.1111/cod.13842
35. Beattie PE, Green C, Lowe G, Lewis-Jones MS. Which children should we patch test? *Clin Exp Dermatol*. Jan 2007;32(1):6-11. doi:10.1111/j.1365-2230.2006.02232.x
36. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Nickel sensitization in adolescents and association with ear piercing, use of dental braces and hand eczema. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). *Acta Derm Venereol*. 2002;82(5):359-64. doi:10.1080/000155502320624096
37. Urwin R, Wilkinson M. Methylchloroisothiazolinone and methylisothiazolinone contact allergy: a new 'epidemic'. *Contact Dermatitis*. Apr 2013;68(4):253-5. doi:10.1111/cod.12064
38. Geier J, Lessmann H, Schnuch A, Uter W. Recent increase in allergic reactions to methylchloroisothiazolinone/methylisothiazolinone: is methylisothiazolinone the culprit? *Contact Dermatitis*. Dec 2012;67(6):334-41. doi:10.1111/j.1600-0536.2012.02157.x
39. Lundov MD, Thyssen JP, Zachariae C, Johansen JD. Prevalence and cause of methylisothiazolinone contact allergy. *Contact Dermatitis*. Sep 2010;63(3):164-7. doi:10.1111/j.1600-0536.2010.01774.x
40. Mowad CM. Methylchloro-isothiazolinone revisited. *Am J Contact Dermat*. Jun 2000;11(2):115-8. doi:10.1053/ac.2000.6344
41. Boonstra MB, Christoffers WA, Coenraads PJ, Schuttelaar ML. Patch test results of hand eczema patients: relation to clinical types. *J Eur Acad Dermatol Venereol*. May 2015;29(5):940-7. doi:10.1111/jdv.12735
42. Simonsen AB, Ruge IF, Quaade AS, Johansen JD, Thyssen JP, Zachariae C. High incidence of hand eczema in Danish schoolchildren following intensive hand hygiene during the COVID-19 pandemic: a nationwide questionnaire study. *Br J Dermatol*. Nov 2020;183(5):975-976. doi:10.1111/bjd.19413
43. Meding B, Gronhagen CM, Bergstrom A, Kull I, Wrangsjo K, Liden C. Water Exposure on the Hands in Adolescents: A Report from the BAMSE Cohort. *Acta Derm Venereol*. Feb 8 2017;97(2):188-192. doi:10.2340/00015555-2505
44. Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. *J Eur Acad Dermatol Venereol*. Dec 2015;29(12):2417-22. doi:10.1111/jdv.13308
45. Diepgen TL, Andersen KE, Brandao FM, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. *Br J Dermatol*. Feb 2009;160(2):353-8. doi:10.1111/j.1365-2133.2008.08907.x
46. Johansen JD, Hald M, Andersen BL, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group. *Contact Dermatitis*. Jul 2011;65(1):13-21. doi:10.1111/j.1600-0536.2011.01911.x

47. Molin S, Diepgen TL, Ruzicka T, Prinz JC. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. *Clin Exp Dermatol*. Aug 2011;36(6):595-601. doi:10.1111/j.1365-2230.2010.04001.x
48. Silverberg JI, Guttman-Yassky E, Agner T, et al. Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. *Dermatitis*. Sep 30 2020;doi:10.1097/DER.0000000000000659
49. Simonsen AB, Deleuran M, Mortz CG, Johansen JD, Sommerlund M. Allergic contact dermatitis in Danish children referred for patch testing - a nationwide multicentre study. *Contact Dermatitis*. Feb 2014;70(2):104-11. doi:10.1111/cod.12129
50. Toledo Alberola F, Silvestre Salvador JF, Latorre Martínez N, Cuesta Montero L, Monteagudo Paz A, Betlloch Mas I. Utility of patch-tests in childrens hand eczema: Comparative study with eczema in the pediatric population and with adult hand eczema. Conference Abstract. *Contact Dermatitis*. 2010;63:68. doi:10.1111/j.1600-0536.2010.01795.x
51. Minh PPT, Minh TT, Huu DL, et al. Using Patch Testing to Improve Therapeutic Outcome in the Treatment of Hand Eczema in Vietnamese Patients. *Open Access Maced J Med Sci*. Jan 30 2019;7(2):204-207. doi:10.3889/oamjms.2019.051
52. Agner T, Andersen KE, Brandao FM, et al. Contact sensitisation in hand eczema patients-relation to subdiagnosis, severity and quality of life: a multi-centre study. *Contact Dermatitis*. Nov 2009;61(5):291-6. doi:10.1111/j.1600-0536.2009.01630.x
53. Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Diepgen TL, Apfelbacher C. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. *Br J Dermatol*. Aug 2014;171(2):304-12. doi:10.1111/bjd.12819
54. Shroff A, Malajian D, Czarnowicki T, et al. Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema. *Int J Dermatol*. Aug 2016;55(8):e447-53. doi:10.1111/ijd.13205
55. Ronsch H, Apfelbacher C, Brans R, et al. Which outcomes have been measured in hand eczema trials? A systematic review. *Contact Dermatitis*. Apr 2019;80(4):201-207. doi:10.1111/cod.13212
56. Eustace K, Dolman S, Alsharqi A, Sharpe G, Parslew R. Use of Phototherapy in Children. *Pediatr Dermatol*. Mar 2017;34(2):150-155. doi:10.1111/pde.13072
57. Christoffers WA, Coenraads PJ, Svensson A, et al. Interventions for hand eczema. *Cochrane Database Syst Rev*. Apr 26 2019;4:CD004055. doi:10.1002/14651858.CD004055.pub2
58. Data presented at the International Society of Atopic Dermatitis 2022 Meeting, October 18, 2022.
59. English J, Aldridge R, Gawkrodger DJ, et al. Consensus statement on the management of chronic hand eczema. *Clin Exp Dermatol*. Oct 2009;34(7):761-9. doi:10.1111/j.1365-2230.2009.03649.x
60. Silvestre Salvador JF, Heras Mendaza F, Hervella Garces M, et al. Guidelines for the Diagnosis, Treatment, and Prevention of Hand Eczema. *Actas Dermosifiliogr*. Jan 2 2020;111(1):26-40. Guia para el diagnostico, el tratamiento y la prevencion del eccema de manos. doi:10.1016/j.ad.2019.04.005
61. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. *Contact Dermatitis*. May 2022;86(5):357-378. doi:10.1111/cod.14035

62. Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. *Expert Opin Investig Drugs*. Aug 2022;31(8):843-853. doi:10.1080/13543784.2022.2087059

Table legend

Table I. Study Data on the Prevalence of Hand Eczema in Pediatrics

Table II. Study Data on Risk Factors for Pediatric Hand Eczema

Table III. Study Data on the Physical Distribution of Hand Eczema in Pediatrics

Table IV. Study Data of Diagnoses Associated with Pediatric Hand Eczema

Table I. "Study Data on the Prevalence of Hand Eczema in Pediatrics"

Table I: Study Data on the Prevalence of Hand Eczema in Pediatrics

							No. of Participants Reporting				No. of Females Reporting			No. of Males Reporting	
Source	**Setting**	**Study Design (Years)**	**Age of Study Participants Included (Years)**	**No. of Total Participants**	**No. of Females**	**No. of Males**	**Lifetime Prevalence of Hand Eczema (%)**	**1-year Prevalence of Hand Eczema (%)**	**Current Hand Eczema (%)**		**Lifetime Prevalence of Hand Eczema (%)**	**1-year Prevalence of Hand Eczema (%)**		**Lifetime Prevalence of Hand Eczema (%)**	**1-year Prevalence of Hand Eczema (%)**
Grönhagen et al., 2014	Sweden; Birth registry	Birth cohort (1994-2012)	0-16	2927	1494	1433	284 (9.7)	152 (5.2)	NR		168 (11.2)	95 (6.4)		116 (8.1)	57 (4.0)
Johannisson et al., 2013	Sweden; 4 schools	Prospective Cohort (1995)	16-19	1516	857	659	202 (13.3)	NR	NR		139 (16.2)	NR		63 (9.6)	NR
Mortz et al., 2001	Denmark; 40 schools	Cross-sectional (1995-1997)	12-16	1438	713	725	133 (9.2)	105 (7.3)	46 (3.2)		87 (12.2)	72 (10.1)		46 (6.3)	33 (4.6)
Wang et al., 2021	Germany; 4 regions	Cross-sectional (2012-2014)	15	1468	715	753	153 (10.4)	NR	NR		91 (12.7)	NR		62 (8.2)	NR
Yngveson et al., 1998	Sweden; 4 schools	Cross-sectional (1995)	16-19	2572	1314	1258	NR	257 (10.0)	108 (4.2)		NR	322 (12.5)		NR	188 (7.3)

NR, Not reported

Table II. "Study Data on Risk Factors for Pediatric Hand Eczema"

Table II: Study Data on Risk Factors for Pediatric Hand Eczema

					Odds Ratio of Association Between				
Source	**Setting**	**Study Design (Years)**	**Age of Study Participants Included (Years)**	**No. of Total Participants**	**Female Sex and HE (95% CI)**	**AD and HE (95% CI)**	**Asthma and HE (95% CI)**	**Allergic Rhinitis and HE (95% CI)**	**Nickel Allergy and HE (95% CI)**
Grönhagen et al., 2015	Sweden; Birth registry	Birth cohort (1994-2012)	0-16	2927	NR	3.7 (2.0-7.0) (P<0.01)	1.5 (0.8-2.5) (P=0.2), 1.2 (0.6-2.1) (P=0.6)[†]	NR	NR
Mortz et al., 2001	Denmark; 40 schools	Cross-sectional (1995-1997)	12-16	1438	NR	5.61 (3.81-8.25) (P<0.001)	1.58 (1.01-2.46) (P < 0.05) (Insignificant after Bonferroni correction)[‡]	NR	NR
Röhrl and Stenberg, 2010	Sweden; 11 schools	Cross-sectional (2000-2004)	14-24	7543	2.0 (1.3-3.2)	4.5 (3.3–6.1)	1.48 (1.04–2.09)	1.8 (1.3–2.5)	1.7 (1.1-2.7)
Silverberg et al., 2021	USA, Canada; >20 clinics	Retrospective (2000-2016)	0-18	1634	0.525 (0.497-0.554) (P=0.6341)	0.989 (0.684-1.431) (P=0.9550)	0.622 (0.378-1.023) (P=0.0615)	0.782 (0.511-1.197) (P=0.2578)	0.539 (0.349-0.832) (P=0.00525)
Wang et al., 2021	Germany; 4 regions	Cross-sectional (2012-2014)	15	1468	1.5 (0.9-2.6) (P=0.090)	1.8 (1.1-2.8) (P=0.019)	NR[‡]	1.4 (0.8-2.5) (P=0.250)	NR

AD, Atopic dermatitis; *CI*, Confidence interval; *HE*, Hand eczema; *NR*, Not reported
[†]Also included allergic rhinitis in their calculation
[‡]Not reported in multivariable logistic regression analysis

Table III. "Study Data on the Physical Distribution of Hand Eczema in Pediatrics"

Table III: Study Data on the Physical Distribution of Hand Eczema in Pediatrics

						Out of All Participants Reporting Lifetime Prevalence of Hand Eczema, No. of Those with				
Source	**Setting**	**Study Design (Years)**	**Age of Study Participants Included (Years)**	**No. of Total Participants**	**No. of Participants with Lifetime Prevalence of Hand Eczema (%)**	**Hand Diffusely Affected (%)**	**Fingers / Finger-webs / Lateral fingers (%)**	**Dorsal hands (%)**	**Palms (%)**	**Fingertips (%)**
Dotterud & Falk, 1995	Norway; Multiple schools	Cross-sectional (1995)	7-12	551	36 (6.5)	NR	NR	14 (38.9)	1 (2.8)	NR
Lee et al., 2001	South Korea; 1 hospital	Cross-sectional (1997-1998)	0.5-12	108	62 (57.0)	NR	NR[†]	38 (61.3)	48 (77.4)	NR
Mortz et al., 2001	Denmark; 40 schools	Cross-sectional (1995-1997)	12-16	1438	133 (9.2)	NR	86 (64.7)	68 (51.1)	22 (16.5)	NR
Ortiz-Salvador et al., 2018	Spain; 1 hospital	Retrospective observational (1996-2016)	0-16	389	42 (10.8)	12 (28.6)	4 (9.5)	5 (11.9)	9 (21.4)	12 (28.6)
Toledo et al., 2011	Spain; 11 hospitals	Retrospective multicenter (2005-2009)	0-15	480	111 (23.1)	19 (17.1)	15 (13.5)	7 (6.3)	29 (26.1)	14 (12.6)

NR, Not reported
[†]Separately reported affected dorsal and ventral surfaces of fingers of right and left hands

Table IV. "Study Data of Diagnoses Associated with Pediatric Hand Eczema"

Table IV: Study Data of Diagnoses Associated with Pediatric Hand Eczema

							No. of Participants with Hand Eczema Diagnosed with			
Source	**Setting**	**Study Design (Years)**	**Age of Study Participants Included (Years)**	**No. of Total Participants**	**No. of Participants with Lifetime Prevalence of Hand Eczema (%)**	**Atopic Dermatitis (%)**	**Allergic Contact Dermatitis (%)**	**Irritant Contact Dermatitis (%)**	**Hyperkeratotic Eczema (%)**	**Vesicular Eczema (%)**
Ortiz-Salvador et al., 2018	Spain; 1 hospital	Retrospective observational (1996-2016)	0-16	389	42 (10.8)	15 (35.7)	14 (33.3)	2 (4.8)	5 (11.9)	6 (14.3)
Silverberg et al., 2021	USA, Canada; >20 clinics	Retrospective (2000-2016)	0-18	1634	237 (14.5)	88 (37.1)	117 (49.4)	40 (16.9)	NR	10 (4.2)
Toledo et al., 2011	Spain; 11 hospitals	Retrospective multicenter (2005-2009)	0-15	480	111 (23.1)	32 (28.8)	40 (36)	17 (15.3)	NR	18 (16.2)

NR, Not reported

Capsule summary (Max word count of 50 words):

- Pediatric chronic hand eczema has a high prevalence yet has not been extensively studied in children and adolescents with no guidelines on its management
- This review on pediatric chronic hand eczema highlights major findings in the literature and supports the need for further investigation into this life-changing disease process